High-risk DLBCL: interim PET? Not yet

被引：3

作者：

Hertzberg, Mark ^{[1
]}

机构：

[1] Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China

来源：

BLOOD | 2017年 / 130卷 / 11期

关键词：

B-CELL LYMPHOMA; TRANSPLANTATION; RITUXIMAB; SUVMAX;

D O I：

10.1182/blood-2017-07-797381

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this issue of Blood, Casasnovas et al demonstrate that among diffuse large B-cell (DLBCL) patients with age-adjusted International Prognostic Index (aaIPI) 2-3, the dose-dense immunochemotherapy (IC) regimen rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVBP) was no better than rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP14). Using an interim positron emission tomography (PET)-adapted approach to consolidation therapy, they show that quantitative rather than qualitative PET assessment may better select some patients needing alternative treatments, including autologous stem cell transplantation (ASCT).(1)

引用

页码：1277 / 1278

页数：2

共 50 条

[21] Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL
Macaulay, Charles
Alig, Stefan
Kurtz, David M.
Jin, Michael C.
Opat, Stephen
Soo, Joanne
Sworder, Brian
Hertzberg, Mark S.
Gandhi, Maher K.
Diehn, Maximilian
Alizadeh, Ash A.
BLOOD, 2019, 134
[22] INTERIM STORAGE FOR SELF-HEATING ELEMENTS WITH HIGH-RISK POTENTIAL
SCHMIDT, K
PTB-MITTEILUNGEN, 1979, 89 (05): : 341 - 343
[23] Frailty Tools are Not Yet Ready for Prime Time in High-Risk Identification
Sheehan, Orla C.
Leff, Bruce
Ritchie, Christine S.
JOURNAL OF HOSPITAL MEDICINE, 2019, 14 (07) : 450 - 450
[24] Daratumumab for high-risk smoldering multiple myeloma-Are we there yet?
Lal, Bhavesh Mohan
Al Hadidi, Samer
EUROPEAN JOURNAL OF CANCER, 2025, 220
[25] Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
Wenzl, Kerstin
Stokes, Matthew E.
Novak, Joseph P.
Bock, Allison M.
Khan, Sana
Hopper, Melissa A.
Krull, Jordan E.
Dropik, Abigail R.
Walker, Janek S.
Sarangi, Vivekananda
Mwangi, Raphael
Ortiz, Maria
Stong, Nicholas
Huang, C. Chris
Maurer, Matthew J.
Rimsza, Lisa
Link, Brian K.
Slager, Susan L.
Asmann, Yan
Mondello, Patrizia
Morin, Ryan
Ansell, Stephen M.
Habermann, Thomas M.
Witzig, Thomas E.
Feldman, Andrew L.
King, Rebecca L.
Nowakowski, Grzegorz
Cerhan, James R.
Gandhi, Anita K.
Novak, Anne J.
BLOOD CANCER JOURNAL, 2024, 14 (01):
[26] Prognostic impact of germinal center associated proteins and chromosomal breakpoints in high-risk DLBCL
van Imhoff, GW
Boerma, EG
van der Holt, B
Kluin-Nelemans, JC
Kluin, PM
ANNALS OF ONCOLOGY, 2005, 16 : 36 - 36
[27] Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL
Jiexian Ma
Shunrong Sun
Yingwei Hu
Min Wu
Lin Shen
Wulipan Fulati
Zilan Huang
Wensi Qian
Pingping Chen
Mingyue Chen
Yanhui Xie
Bone Marrow Transplantation, 2022, 57 : 1612 - 1614
[28] Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL
Ma, Jiexian
Sun, Shunrong
Hu, Yingwei
Wu, Min
Shen, Lin
Fulati, Wulipan
Huang, Zilan
Qian, Wensi
Chen, Pingping
Chen, Mingyue
Xie, Yanhui
BONE MARROW TRANSPLANTATION, 2022, 57 (10) : 1612 - 1614
[29] CNS relapse in young high-risk DLBCL patients - a joint analysis of LYSA and GLA
Frontzek, F.
Altmann, B.
Ziepert, M.
Casasnovas, O.
Morschhauser, F.
Oberic, L.
Poeschel, V
Fitoussi, O.
Held, G.
Glass, B.
Ketterer, N.
Renaud, L.
Lenz, G.
Mounier, N.
Rosenwald, A.
Ott, G.
Molina, T.
Parrens, M.
Chartier, L.
Tilly, H.
Thieblemont, C.
Schmitz, N.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 16 - 17
[30] Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients
Zhao, Ying
Wang, Hong
Jin, Song
Zheng, Jiajia
Huang, Man
Tang, Yaqiong
Jin, Zhengming
Qiu, Huiying
Tang, Xiaowen
Fu, Chengcheng
Han, Yue
Wu, De-Pei
ONCOTARGET, 2017, 8 (42) : 73168 - 73176

← 1 2 3 4 5 →